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Purpose: To compare inhibition of HIV replication, improvements in CD4+ T-cell
counts, metabolic parameters, and body shape changes after 2 years of assigned
therapy in OzCombo patients. Method: Study participants were those who were
recruited into the open-label OzCombo 1 (1996/1997) and OzCombo 2 (1997/1998)
trials. Patients in OzCombo 1 were randomized to receive indinavir in combination
with zidovudine+lamivudine (AZT+3TC; n = 35), stavudine (d4T)+3TC (n = 34), or
d4T+didanosine (ddI) (n = 37). OzCombo 2 patients were randomized to the same
nucleoside reverse transcriptase inhibitor (NRTI) backbones with nevirapine (n = 20,
22, 23, respectively). The mean time-weighted changes from baseline in CD4 T-cell
count/mL, HIV RNA (log copies/mL plasma), and proportions with detectable viral
load (>500 copies plasma HIV RNA/mL) between NRTI arms over 2 years were
compared by formal meta-analysis. A cross-sectional study of metabolic and body
shape complications was also undertaken. Results: For the comparison of d4T+3TC
and d4T+ddI to AZT+3TC, mean differences in time-weighted change from baseline
in CD4 T-cell count/µL and log copies HIV RNA/mL adjusted for baseline CD4+ T-cell
and HIV RNA counts were: -44 (p = .08) and -14 (p = .56) cells/µL and  -0.1 (p = .40)
and -0.1 (p = .6) copies/mL. Odds ratios for detectable viral load in the last study
quarter were 0.6 (p = .44) and 1.0 (p = .95). The mean percent leg fat was lower in the
d4T+3TC and d4T+ddI than the AZT+3TC arm (mean difference 5.1% [p = .07] and
7.6% [p = .02], respectively). Conclusion: For all regimens, virological control and
immunological response were maintained over 2 years. Regimens containing d4T
and particularly d4T+ddI were significantly associated with increased peripheral fat
loss compared with AZT+3TC. Key words: antiretroviral therapy, highly active, HIV-
1, lipodystrophy, meta-analysis, virological failure
T
he use of highly active antiretroviral therapy
(HAART) containing three or more drugs is
now recommended treatment for HIV
infection.1,2  Most randomized controlled studies
designed to evaluate the efficacy of HAART in
terms of virological, immunological, and clinical
outcomes have only been conducted over 48 to 52
weeks. Most of these studies have described
*See Appendix for complete list
inhibition of HIV replication to undetectable levels
in the majority of patients. However, longer term
outcomes have not been well described.OZCOMBO 1 & 2 LONG-TERM FOLLOW-UP •A MIN ET AL. 253
The OzCombo 1 and OzCombo 2 studies com-
pared dual nucleoside reverse transcriptase inhibi-
tor (NRTI) backbones (zidovudine+lamivudine
[AZT+3TC]; stavudine [d4T]+3TC;
d4T+didanosine [ddI]), in combination with
indinavir (IDV) in OzCombo 1 and nevirapine
(NVP) in OzCombo 2. The outcomes of these trials
have been reported previously with no difference
found in immunological or virological endpoints at
1 year.3,4 To determine whether the observed im-
pact of treatment on viral suppression and immu-
nological improvement could be sustained, pa-
tients participating in these two randomized
controlled trials were followed up to 2 years after
randomization. During the conduct of these stud-
ies, reports were made of adverse metabolic and
morphologic effects arising from the use of
antiretroviral therapy in individuals with HIV in-
fection.5–7 Thus, a cross-sectional substudy was also
conducted to assess the frequency of these abnor-
malities.
METHOD
Participants
All 106 participants enrolled in OzCombo 1 and
65 from OzCombo 2 were included in this study.3,4
The main eligibility criteria of these trials included
documented HIV infection, age greater than 18
years, and no prior antiretroviral therapy.
OzCombo 1 patients were required to have a CD4+
T-cell count less than 500 cells/µL or HIV RNA
load greater than 30,000 copies/mL plasma,
whereas OzCombo 2 required CD4+ T-cell count
greater than 50 cells/µL with no restriction on viral
load.
Interventions and Assessments
Patients in OzCombo 1 were randomized to re-
ceive IDV in combination with AZT+3TC (n = 35),
d4T+3TC (n = 34), or d4T+ddI (n = 37). OzCombo 2
patients were randomized to the same NRTI back-
bones with NVP (n  = 20, 22, 23, respectively).
Drugs were prescribed at the manufacturers’ rec-
ommended doses: AZT 250 mg, 3TC 150 mg, d4T
40 mg, ddI 200 mg, NVP 200 mg twice daily, and
IDV 800 mg three times a day. Dose modifications
of ddI and d4T were recommended for patients
with body weight <60 kg. Patients received an ini-
tial dose of NVP 200 mg daily for 2 weeks increas-
ing to 200 mg bid. Drug substitution within the
same class was mandatory for recurrent grade 3 or
4 drug-related adverse events and was optional for
persistent drug-related grade 1 to 2 adverse events
or for therapeutic failure. No interventions beyond
initial randomized treatment were instigated as
part of long-term follow up. Real-time plasma HIV
RNA load, CD4+ T-cell count, and changes in
antiretroviral therapy data were collected on all
randomized patients who consented to long-term
follow-up at as close to 12 weekly intervals as pos-
sible from day of randomization until 31 January
2001 (close of study). Plasma HIV RNA levels were
measured using Amplicor Version 1.0 (Roche Di-
agnostics, Branchburg, New Jersey, USA; lower de-
tection limit of 500 copies/mL plasma). CD4+ T-
cell counts were determined by dual-color flow
cytometry.
Statistical Analyses
All analyses were conducted to compare the ran-
domized treatment nucleoside backbones
AZT+3TC versus d4T+3TC versus d4T+ddI. The
primary study endpoints were the time-weighted
mean change from randomization in plasma HIV
RNA copies and CD4+ T-cell count, the propor-
tions of patients with plasma HIV RNA <500 cop-
ies/mL, and the proportion of patients with a new
AIDS-defining event (CDC category C) at 2 years.
Changes in plasma HIV RNA copies and CD4+
T-cell count from baseline were summarized by
nominal study weeks using a time window ap-
proach; the average value was used if there was
more than one value in a time window. Time win-
dows for the first 52 weeks of the studies are as
used previously.3,4  Twelve-week time windows
were used for the second year of follow-up until
Week 104, which included data to the end of 130
weeks.
To account for differences in inclusion criteria
between trials and potential confounding vari-
ables, analyses were adjusted for baseline CD4+T-
cell count and plasma HIV RNA copies using re-
gression techniques. All analyses were conducted
on the basis of intention to treat for available data;
missing-equals-failure analysis is also presented
for proportion of patients with detectable viral
load. Data from OzCombo 1 and 2 were combined
by fixed effects meta-analysis using STATATM 7.0254 HIV CLINICAL TRIALS •4 / 4•J ULY-AUG 2003
(Stata Corp., College Station, Texas, USA).8  All
analyses were undertaken to compare the random-
ized NRTI backbones. Comparisons between IDV
and NVP were not undertaken, as these assign-
ments were not randomized. An implicit assump-
tion of this analysis is that NRTI backbone effects
were qualitatively similar regardless of combina-
tion with either IDV or NVP. Tests for heterogene-
ity between trial and treatment were not statisti-
cally significant (p > .05 for all endpoints, data not
shown).
Metabolic and Morphologic Adverse Affects
Substudy
All randomized patients were eligible to partici-
pate in this substudy, which was conducted in
1999. The substudy required additional informed
consent. Ethics committees of participating sites
approved both the protocol and informed consent.
The protocol required the collection of HIV history
and demographics, antiretroviral therapy, clini-
cian- and patient-diagnosed clinical features of li-
podystrophy syndrome, laboratory data (including
fasted lipid and glycemic profiles), skin fold thick-
nesses, abdominal (L4) CT scans, and dual-energy
X-ray absorptiometry scans (all data not shown).
As far as was possible, all data were to be collected
from a single patient within a 3-month window. All
data from all patients were collected within a 6-
month window. Procedures for collection of DEXA
and CT scan data were uniform, and imaging by
DEXA was performed using identical equipment
(LUNAR) and software. Presence and severity of
peripheral (face, arms, legs, lipomatosis, promi-
nent veins, buttocks), central (abdomen, breasts,
and buffalo hump), and overall (peripheral and
central) lipodystrophy were assessed indepen-
dently by clinicians and patients. In each region, a
score of 0 was assigned for no change and 1 for any
fat loss.
Patient characteristics and measures of meta-
bolic abnormality or fat change were summarized
and analyzed by t  test for continuous outcomes
and logistic regression for binary outcomes on the
basis of originally assigned nucleoside treatment
group. Data from both trials were again combined
by fixed effects meta-analysis.
RESULTS
Patient Accountability
One hundred and seventy-one patients began
assigned treatment in the OzCombo 1 and 2 trials.
The median time of follow-up was 152 weeks
(interquartile range [IQR], 100–180 weeks). By
Week 52, 168 (98%) patients remained in follow-up;
this fell to 132 (77%) by Week 104 (Table 1). Main-
tenance in follow-up was greatest in the d4T+3TC
arm (86%), followed by the d4T+ddI arm (77%) and
then the AZT+3TC arm (69%).
Patient Characteristics
Patient characteristics at baseline were similar
across treatment arms (Table 2). OzCombo 1 pa-
tients comprised 62% of the patient population.
This proportion was consistent across study arms.
CD4+ T-cell counts were slightly higher in the
d4T+3TC arm. The ddI+d4T arm had fewer men.
All baseline AIDS-defining conditions (Centers for
Disease Control category C) occurred in patients
enrolled in OzCombo 1.
Table 1.  Patient allocation and follow-up
Randomized treatment
AZT+3TC d4T+3TC d4T+ddI Total
n (%) n (%) n (%) n (%)
Week 0 55 56 60 171
Week 52 55 (100) 54 (96) 58 (97) 168 (98)
Week 104 38 0(69) 48 (86) 46 (77) 132 (77)
Note: AZT = zidovudine, 3TC = lamivudine, d4T = stavudine, ddI = didanosine.OZCOMBO 1 & 2 LONG-TERM FOLLOW-UP •A MIN ET AL. 255
Treatment Outcomes
At Week 52, of those who had ceased an assigned
drug, more had ceased one or more of their NRTIs
than IDV or NVP (24% vs. 15%, McNemar’s p =
.0001) (Figure 1). This difference was most marked
in the d4T+ddI arm in which 30% of participants
had ceased an NRTI and 10% had ceased IDV or
NVP (McNemar’s p < .0001).
At Week 104, 85 (64%) patients were still on as-
signed treatment, with proportions by treatment
varying from 82%, 67%, to 46% for the AZT+3TC,
d4T+3TC, and d4T+ddI (χ2 p = .002) arms, respec-
tively. In the d4T+ddI arm, the proportion of par-
ticipants who had ceased an NRTI (54%) was more
than double that in the other arms (AZT+3TC, 16%;
d4T+3TC, 21%; χ2 p = .0001).
By the end of Week 52, there were three AIDS-
Table 2.  Baseline characteristics, pooled from OzCombo 1 and 2
AZT+3TC d4T+3TC d4T+ddI
n = 55 n = 56 n= 60
OzCombo 1 [n (%)]a 35 (64) 34 (61) 37 (62)
Males [n (%)] 52 (95) 54 (96) 52 (87)
AIDS [n (%)] 5 (9) 6 (11) 8 (13)
Real time viral load, log10copies/mL
[mean (SD)] 4.60 (0.70) 4.68 (0.66) 4.67 (0.74)
CD4+ count, cells/µL[mean (SD)] 333 (219) 346 (210) 307 (224)
Age, years [mean (SD)] 38 (7.9) 40 (10.5) 36 (9.4)
Weight, kg [mean (SD)] 75 (17.5) 77 (13.7) 70 (10.9)
Note: AZT = zidovudine, 3TC = lamivudine, d4T = stavudine, ddI = didanosine.
aPatients enrolled in OzCombo 1.
Figure 1.  Treatment status of patients by week of follow-up and treatment assignment. AZT = zidovudine, 3TC =
lamivudine, d4T = stavudine, ddI = didanosine, IDV = indinvavir, NVP = nevirapine.256 HIV CLINICAL TRIALS •4 / 4•J ULY-AUG 2003
defining (CDC category C) events, all from
OzCombo 1 and one in each treatment arm. There
were two further events in OzCombo 1 by the end of
Week 104, both in patients on d4T+ddI+IDV. There
were no AIDS events in OzCombo 2 to Week 104.
Virological Responses
Mean plasma HIV RNA level fell from baseline by
almost 2 log copies/mL in all treatment arms within
4 weeks, and at least a 1.6 log copies/mL reduction
was maintained through 104 weeks (Figure 2).
Mean time-weighted changes in log copies plasma
HIV RNA per mL from baseline to Week 104, ad-
justed for baseline CD4+ T-cell count and plasma
HIV RNA copies, were -1.6, -1.8, and -1.7 log10 cop-
ies/mL in the AZT+3TC, d4T+3TC, and d4T+ddI
arms, respectively. The mean differences in time-
weighted change HIV RNA copies from baseline
relative to the AZT+3TC arm were -0.04 (95% CI
-0.12 – 0.19; p = .65) and 0.0 (95% CI -0.07 – 0.08; p =
.91) log10  copies/mL for d4T+3TC and d4T+ddI
arms, respectively. Overall, 22 (17 %) had a plasma
HIV RNA viral load greater than 500 copies/mL at
Week 104, with no statistically significant difference
in proportions between treatment (Table 3). When
patients with missing data were allocated as having
a detectable HIV RNA, the number of patients with
detectable plasma HIV RNA rose to 75 (44%): 49%,
25%, and 57% for the AZT+3TC, d4T+3TC, and
d4T+ddI arms, respectively.
Immunological Responses
In all arms, the CD4+ T-cell count increased by at
least 100 cells/µL by Week 16 and generally contin-
ued to rise to over 200 cells/µL by Week 104 fol-
low-up (Figure 3). The mean time-weighted
changes from baseline to Week 104 in CD4 T-cell
count/mL were 167, 199, and 193 cells/µL in the
AZT+3TC, d4T+3TC, and d4T+ddI arms, respec-
tively.  The mean differences in time-weighted
change from baseline compared with the
AZT+3TC arm, adjusted for baseline CD4 T-cell
count and plasma HIV RNA copies, were -44 (95%
CI -92 – 5; p = .08) and -14 (95% CI -62 – 33; p = .56)
cells/µL for the d4T+3TC and d4T+ddI arms, re-
spectively.
Metabolic and Morphologic Adverse Events
Substudy
In total, 84 (47%) patients from the original
OzCombo 1 and 2 cohorts were recruited into the
Figure 2.  Mean change from baseline in plasma HIV RNA copies/mL. P for difference in mean time-weighted change
from baseline, AZT+3TC referent group. AZT = zidovudine, 3TC = lamivudine, d4T = stavudine, ddI = didanosine.OZCOMBO 1 & 2 LONG-TERM FOLLOW-UP •A MIN ET AL. 257
Table 3.
  Meta-analysis of Week 104 outcomes by treatment arm
AZT+3TC
a
d4T+3TC
d4T+ddI
Mean
Mean
Difference (95% CI)
p
Mean
Difference (95% CI)
p
CD4  TWAUC (cells/µL)
167
199
−
44
(
−
92 
−
 5)
.08
193
−
14
(
−
62 – 33)
.56
HIV RNA TWAU (cells/µL)
−
1.65
−
1.76
−
0.04
(
−
0.12 – 0.19)
.65
−
1.72
0.00
(
−
0.07 – 0.08)
.91
AZT+3TC
a
d4T+3TC
d4T+ddI
n
 (%)
n
 (%)
OR
(95% CI)
pn
 (%)
OR
(95% CI)
p
HIV RNA >500 copies/mL
7(18)
6(13)
0.60
(0.17 – 2.17)
.44
9 (20)
1.04
(0.33 – 3.21)
.95
Note:
 
Adjusted for baseline CD4 T-cell count and baseline HIV RNA copies. TWAUC = time-weighted change from baseline to Week 104, ar
ea under
curve.
a
Reference group258 HIV CLINICAL TRIALS •4 / 4•J ULY-AUG 2003
substudy. The patient distribution was 21 (59%), 35
(35%), and 28 (35%) for the AZT+3TC, d4T+3TC,
and d4T+ddI arms, respectively. Significant differ-
ences between nucleoside arms were detected for
variables related to peripheral fat changes. Com-
pared to the AZT+3TC referent arm, proportion of
fat mass in legs was significantly less in the
d4T+3TC (5.1%) and d4T+ddI (7.6%) nucleoside
arms (Table 4). Patient- and clinician-reported pe-
ripheral fat loss also had significantly greater odds
of being associated with d4T+3TC (OR 4.0, 95% CI
1.1–14.5, and OR 6.7, 95% CI 1.6–27.6) and d4T+ddI
(OR 8.0, 95% CI 2.0–32.0, and OR, 4.1, 95% CI 1.0–
16.3) compared with AZT+3TC. The d4T+ddI
group had the lowest mean BMI (22.7 kg/m2, p =
.02). There were no significant differences between
treatment arms in other metabolic and body com-
position endpoints (data not shown).
DISCUSSION
Of the 171 patients randomized in OzCombo 1
and 2 to AZT+3TC, d4T+3TC, or d4T+ddI in com-
bination with either IDV or NVP, 77% remained in
follow-up and 64% were still on their assigned regi-
men at Week 104. Virological and immunological
responses were maintained over the 2 years of fol-
low-up, with no significant difference between ran-
domized treatment arms. However, peripheral
lipoatrophy was significantly increased in patients
assigned to treatment with d4T+3TC or d4T+ddI.
The 36% assigned therapy discontinuation rate
reported in our study is within the 36%–43% range
reported in other long-term follow-up studies of
antiretroviral-naïve patients.9,10 The lower propor-
tion of patients maintaining d4T regimens, particu-
larly in combination with ddI, during the second
year of follow-up is consistent with reports of de-
clining use of d4T+3TC- and d4T+ddI-containing
regimens since 1999 in the Australian HIV Obser-
vational Database.11  Patients on ddI were also
found to have the highest stopping rate in the
Royal Free Hospital cohort study, with  an inci-
dence of stopping of  41.6% per 10 person-years of
follow-up.12
Although reasons for stopping antiretroviral
therapy were not collected in this study, other
studies report the primary reasons for stopping as
toxicity (21.1%–42.7%), failure (5%–28%), and non-
adherence (7.1%–23%).9,10  In the d’Armino
Monforte study, the median follow-up time was
much shorter than in this study at 45 weeks, with
most toxicity-related discontinuations occurring
earlier (median 84 days) and discontinuations due
to failure occurring later (median 270 days).9 How-
ever, the plateau in plasma HIV RNA levels and
Figure 3.  Mean change from baseline in CD4+ T-cell count/mL. P for difference in mean time-weighted change from
baseline, AZT+3TC referent group. AZT = zidovudine, 3TC = lamivudine, d4T = stavudine, ddI = didanosine.OZCOMBO 1 & 2 LONG-TERM FOLLOW-UP •A MIN ET AL. 259
continued increase in CD4+ T-cell counts over 2
years in our study indicate that the higher discon-
tinuation rates in the second year of the study are
unlikely to be related to failure overall.
The higher discontinuation and loss to follow-
up rates in the d4T-containing arms during the
second year, particularly the arm that included
ddI, may be due to drug toxicity or awareness of
the association between the use of these drugs and
lipodystrophy during the late 1990s.6,7 It is prob-
able that lipodystrophy did occur more often in the
d4T+ddI arm as indicated by the significantly in-
creased peripheral fat loss detected in this study
arm. However, the mean baseline weight in this
study arm was lower than other arms, which may
have resulted in these patients being more suscep-
tible to lipodystropy and discontinuation of
therapy. Patient- and clinician-assessed peripheral
fat loss was also significantly greater in the d4T-
containing arms. Stavudine-containing regimens in
general have subsequently been found to be associ-
ated with an increased risk of fat wasting in both
treatment-experienced and -naïve patients.13,14
There are limitations to our study. Even though
the follow-up rate of 77% was reasonable, loss to
follow-up may have led to a bias in study findings.
Table 4.  Body fat distribution and metabolic abnormalities in patients taking part in the morphologic
and metabolic adverse effects substudy
Treatment Mean Difference 95% confidence interval p
Lactate (mmol/L) AZT+3TC 1.42
d4T+3TC 1.35 0.10 −0.25  - 0.44 .58
d4T+ddI 1.66 −0.30 −0.72  - 0.12 .16
Triglyceride (mmol/L) AZT+3TC 1.58
d4T+3TC 2.11 −0.40 −1.13 - 0.34 .29
d4T+ddI 2.09 −0.42 −1.29 - 0.45 .34
HDL cholesterol (mmol/L) AZT+3TC 1.20
d4T+3TC 1.21 −0.01 −0.19 - 0.18 .96
d4T+ddI 1.14 0.08 −0.14 - 0.31 .47
Leg fat (%) AZT+3TC 22.03
d4T+3TC 17.28 5.08 −0.50 - 10.66 .07
d4T+ddI 15.03 7.63 1.15 - 14.12 .02
VAT AZT+3TC 104.13
d4T+3TC 118.66 −20.36 −66.96 - 26.24 .39
d4T+ddI 90.18 11.39 −31.98 - 54.77 .61
SAT AZT+3TC 147.61
d4T+3TC 146.67 1.31 −48.95 - 51.57 .96
d4T+ddI 133.28 11.06 −46.86 - 68.99 .71
BMI (kg/m) AZT+3TC 25.28
d4T+3TC 27.71 0.87 −1.36 - 3.10 .43
d4T+ddI 22.67 2.72 0.44 - 5.00 .02
Proportion Odds ratio
Patient-reported peripheral fat lossa AZT+3TC 19
d4T+3TC 49 3.95 1.08 - 14.45 .04
d4T+ddI 64 7.97 1.98 - 32.06 <.01
Clinician-reported peripheral fat AZT+3TC 19
lossa
d4T+3TC 57 6.71 1.64 - 27.57 <.01
d4T+ddI 46 4.09 1.03 - 16.26 <.05
Note: AZT = zidovudine, 3TC = lamivudine, d4T = stavudine, ddI = didanosine, HDL = high density lipoprotein, VAT = visceral
adipose tissue, SAT = subcutaneous adipose tissue, BMI = body mass index.
aSee text for method of calculation.260 HIV CLINICAL TRIALS •4 / 4•J ULY-AUG 2003
Reasons for stopping therapy were not routinely
collected in the second year of the study. While
they may be deduced on the basis of other studies,
few studies have follow-up over 2 years and there-
fore may not be comparable. The metabolic and
morphological abnormalities substudy was cross-
sectional, a study type with inherent flaws, and the
sample size of this study may have been too small
to detect other differences between NRTI back-
bones. The open-label clinician and patient assess-
ment of lipodystrophy was also open to bias. How-
ever, objective measures of lipodystrophy by
imaging measures were in agreement with the pa-
tient and clinician assessments. Comparisons be-
tween the IDV and NVP treatments were not
made, as assignment to these treatments was not
randomized.
In conclusion, 64% of patients were on assigned
therapy at the end of 2 years. There was a signifi-
cantly higher association of lipodystrophy with
d4T+3TC and d4T+ddI assignment than with
AZT+3TC, and cessation of original treatment was
highest in the d4T+ddI arm. Of patients in follow-up
at 2 years, 83% had undetectable viral load and
achieved a greater than 200 cell/µL mean increase in
CD4 T-cell count, with no significant differences be-
tween NRTI backbones for either clinical measure.
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